Mizuho reiterates Arcus Biosciences stock rating after trial halt By Investing.com

Arcus Biosciences discontinued its Phase 3 STAR-121 lung cancer trial after a futility analysis, and Gilead’s option rights to earlier pipeline assets will expire on July 14, 2026 because the continuation payment was not made. Mizuho kept an Outperform rating and $47 price target, arguing the news was already well telegraphed and that Arcus can refocus spending on casdatifan in clear cell renal cell carcinoma, with ARC-20 data expected later this year. The company also reported Q4 2025 EPS of -$0.89 versus -$1.10 expected, but revenue missed at $33 million versus $35.71 million.

Analysis

This is a classic “de-risking rally” setup for RCUS: the market can stop underwriting a low-probability, capital-intensive domino chain and instead value the remaining pipeline on a cleaner probability tree. The incremental upside is not from the failed asset itself, but from the release of management bandwidth and R&D dollars toward casdatifan, which now becomes the sole near-term re-rating lever and a much easier model for investors to underwrite.

The second-order winner is likely the company’s balance-sheet optionality: with a narrower burn profile, Arcus can preserve flexibility into the 2026 Phase 3 window without needing to pre-sell value via dilutive financing. That matters because oncology biotech multiples typically compress hardest when a company is forced to fund multiple shots on goal; removing one late-stage program reduces the probability of an adverse capital raise over the next 6-12 months.

For GILD, the option expiration is more about signaling than economics. The loss of embedded rights suggests the collaboration no longer functions as a strategic call option on the broader Arcus platform, which slightly weakens Gilead’s external pipeline narrative and reduces its ability to claim breadth in oncology without committing capital. The market may underappreciate that this also shifts negotiating leverage on future partnership economics toward Arcus if casdatifan data read through cleanly.

Contrarianly, the stock’s prior rerating may not be as insulated as bulls think: once the market removes the failed assets, the remaining valuation becomes more binary on a single program and a single data cadence. Near-term catalysts are early-line readouts and the casdatifan franchise update, while the main risk over the next 3-9 months is a ‘good but not great’ dataset that validates activity but not enough differentiation to justify a premium multiple.

Key Decisions for Investors

• Long RCUS on weakness for a 3-6 month trade: use the post-event reset to build a position ahead of early-line ARC-20 data; upside comes from multiple expansion if casdatifan emerges as a credible lead asset, while downside is limited by the cleaner balance-sheet story.
• Sell RCUS upside calls against spot for investors already long: monetize the event-driven pop and cap exposure into a binary data window; this is attractive if implied volatility remains elevated versus the probability of a merely incremental readout.
• Pair trade: long RCUS / short a basket of later-stage oncology names with multiple expensive, non-differentiated assets; the cleaner pipeline and lower capital drag should outperform peers that still need to fund several programs simultaneously.
• Short-dated tactical hedge on RCUS using put spreads into the next data catalyst: if the market is extrapolating peak-sales rhetoric too aggressively, a 1-2 quarter miss in data quality could compress the stock sharply from current levels.
• For GILD holders, do not overreact operationally, but consider a relative-value hedge via short RCUS against GILD only if you want to isolate collaboration drag; the economic impact to GILD is modest, but the strategic signal may pressure sentiment around external innovation.